AVITA Medical & Gates Center unite to explore spray-on skin treatment
Category: #health  By Pankaj Singh  Date: 2019-11-25
  • share
  • Twitter
  • Facebook
  • LinkedIn

AVITA Medical & Gates Center unite to explore spray-on skin treatment

AVITA Medical and Gates Center for Regenerative Medicine have reportedly inked a Sponsored Research Agreement or SRA to develop treatments for genetic skin conditions. The firms will conduct preclinical trials to develop spray-on skin treatments using genetically modified skin cells to treat epidermolysis bullosa (EB) patients as well as other genetic skin disorders.

This collaboration will bring together AVITA Medical’s patented Spray-On Skin™ Cells technology and Gates Center’s unique, patent-pending gene editing and combined reprogramming technology to improve cell function. As per the SRA terms, AVITA Medical will retain the option to obtain an exclusive license for further progression and commercialization of technologies that emerge during the collaboration.

The Gates Center team is backed by numerous prominent medical organizations. The collective efforts of the New York-based EB Research Partnership, London-based Cure EB Charity, L.A-based EB Medical Research Foundation, as well as government grants will help advance and render this technology to clinics to enhance patient lives.

Dr. Mike Perry, CEO of AVITA Medical & adjunct professor at the Gates Center has apparently stated that the Gates center has made significant strides in the treatment of genetic skin conditions, particularly epidermolysis bullosa.  He further expressed his anticipation towards working together with the Gates Center team to further advance AVITA’s Spray-On Skin™ Cells technology. The collaboration is a significant breakthrough for AVITA in their mission to harness regenerative medicine to treat unmet dermatological needs, including genetic skin disorders.

Gates Center for Regenerative Medicine Director, Dr. Dennis Roop also spoke about the partnership, expressing his eagerness to partner with AVITA Medical in an effort to further their epidermolysis bullosa program. He stated that this alliance will help discover and advance new approaches towards genetic skin conditions, by treating patients through the use of gene-edited skin cells.

Dr. Ganna Bilousova, assistant professor of dermatology & the research program’s co-principal investigator has also expressed his belief that the combination of AVITA’s Spray-On Skin™ Cells technology and Gates Center’s genetically modified skin cells will help advance their EB treatment program. Dr. Bilousova claims that this collaboration will help reduce treatment time, lower manufacturing complexity and improve treatment results, in addition to lowering costs.

Source Credit: https://www.avitamedical.com/uploads/pdf/AVH-Press-Release-EB-CU-Denver-Partnership-25NOV2019-FINAL.pdf



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Epizyme gets FDA approval for TAZVERIK™ to treat epithelioid sarcoma
Epizyme gets FDA approval for TAZVERIK™ to treat epithelioid sarcoma
By Pankaj Singh

Epizyme, Inc., a renowned biopharmaceutical company developing new epigenetic therapies, has reportedly announced that the United States Food and Drug Administration has granted the accelerated approval of the company&...

PayPal and UnionPay partner to expand their global consumer base
PayPal and UnionPay partner to expand their global consumer base
By Pankaj Singh

Digital payment applications have simplified cashless transactions by offering payment options in both offline and online mode. Within a short span of time, the digital payment industry has seen significant growth, wit...

Eli Lilly and Company to build a manufacturing unit in North Carolina
Eli Lilly and Company to build a manufacturing unit in North Carolina
By Pankaj Singh

Global pharmaceutical firm, Eli Lilly and Company has recently revealed plans to create over 460 new jobs by investing nearly $470 million in Durham, North Carolina. Reportedly, the project would introduce a brand new ...